I

Intuitive Surgical

Builds robots for minimally invasive surgery

Talent Acquisition Consultant

Full-TimeUpdated on 10/23/2026
No salary listed
Senior
Bachelor's
Sunnyvale, CA, USA
HybridHybrid schedule: 2–3 days onsite in Sunnyvale.
People & HRGeneralist Recruiting

About the job

Requirements
  • Demonstrated success in agency or corporate recruiting, including a strong track record of delivering results.
  • Strong sourcing and talent-identification capabilities, including engaging passive candidates.
  • Ability to build credibility and influence leaders at multiple organizational levels.
  • Strong business acumen and consultative problem-solving skills.
  • Experience using talent market insights and data to shape recruiting strategies and hiring outcomes.
  • Excellent communication, stakeholder-management, and relationship-building skills.
  • Ability to manage multiple searches simultaneously while remaining organized and self-motivated.
  • Experience with applicant tracking systems, customer relationship management systems, and recruiting technologies.
  • A Bachelor's degree is preferred, not required.
Responsibilities
  • Partner with hiring leaders to understand business objectives, workforce plans, and current and future talent needs.
  • Provide market insights, competitive intelligence, and recruiting best practices as a trusted advisor.
  • Influence hiring decisions through data-driven recommendations and talent market expertise.
  • Develop and execute sourcing strategies to identify and attract talent.
  • Build pipelines of diverse, qualified candidates for current and future hiring needs.
  • Engage active and passive candidates through networking, referrals, recruitment marketing, industry events, and direct sourcing.
  • Deliver a strong candidate experience throughout the recruitment lifecycle.
  • Lead the hiring process from intake through offer acceptance, balancing timely execution, quality, and stakeholder expectations.
  • Facilitate interview strategy, candidate assessments, offer discussions, and final hiring decisions.
  • Use recruiting metrics, talent intelligence, and market data to influence decisions and improve outcomes.
  • Identify opportunities to improve recruiting effectiveness, scalability, and candidate experience.
  • Lead or participate in projects that improve the Talent Acquisition function.
  • Support hiring-leader development through training, coaching, and interview best practices.
Desired Qualifications
  • Experience recruiting in healthcare, medical device, life sciences, engineering, or technology environments.
  • Experience partnering directly with business leaders on workforce planning and talent strategy.
  • Experience with Workday, SmartRecruiters, or similar platforms.
  • Demonstrated success recruiting passive talent for highly competitive or hard-to-fill positions.

About the company

Intuitive Surgical makes da Vinci robots that let surgeons operate through a few small incisions, and Ion, a robot that reaches deep into the lungs to take tissue samples. In 2000, da Vinci became the first robotic system cleared by the FDA for general laparoscopic surgery, meaning keyhole operations in the abdomen. A surgeon sits at a nearby console and steers robotic arms holding a 3D camera and wristed instruments, which turn hand movements into smaller, steadier motions. Hospitals buy or lease the robots, then keep paying for the instruments used in each operation and for service. Intuitive was founded in 1995 to commercialize robotic surgery research from SRI International and is based in Sunnyvale, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand keeps compounding: da Vinci procedures grew 15% and revenue 19%, to $2.89 billion, in the June 2026 quarter.
  • Room to grow: Intuitive listed 748 open roles in October 2026, including 191 in engineering and 312 in Sunnyvale.
  • Repeat sales steady the business: instruments and service made 76% of revenue in the June 2026 quarter.

What critics are saying

  • Stock grants have shrunk: shares fell 27% from January to October 2026, versus 9% for rival Medtronic.
  • Device giants are moving in: the FDA cleared rival robots from Medtronic in December 2025 and J&J in July 2026.
  • Instrument sales face a court fight: in August 2026, an appeals court revived a repair firm's monopoly suit against Intuitive.

What makes Intuitive Surgical unique

  • Hospitals rent more than they buy: 254 of 468 da Vinci systems placed in the June 2026 quarter were leases.
  • It runs without borrowing: Intuitive had no debt and $8.6 billion in cash and investments in June 2026.
  • Its CEO is a 30-year insider: Dave Rosa, CEO since July 2025, joined as employee number nine in 1996.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
LinkedIn
Oct 25th, 2026
Ruby Robotics Acquired by Intuitive for Minimally Invasive Care Solutions | Ruby Robotics posted on the topic | LinkedIn

We are excited to announce that in late 2025, Ruby Robotics was acquired by Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery.   Together with Intuitive, we are continuing our mission to improve the accuracy, efficiency, and accessibility of tissue assessment during biopsy procedures at the point of care with integrated robotics and artificial intelligence solutions.   Thank you to our team, investors, advisors, consultants, and contributors whose shared belief in our vision made Ruby a success. To our new Intuitive colleagues: we’re excited to collaborate with you and look forward to making a positive impact on patients and physicians together. E14 Fund Root Ventures Link Ventures SeedFolio Kicker Ventures Celtic House Asia Partners Zelda Ventures Tamer Capital Taiwan Global Angels Cendana Capital UNION | 19 comments on LinkedIn

Yahoo Finance
Oct 1st, 2026
Intuitive Surgical down 30% in 2026, but Wall Street analysts stay bullish

Intuitive Surgical has lost nearly 30% year-to-date in 2026, making it one of healthcare's biggest losers. The stock fell over 40% by late July. Despite this decline, Wall Street remains bullish—24 of 32 analysts surveyed by S&P Global in September rated it a "buy" or "strong buy." The medical device maker faces several challenges. Growth is slowing whilst the stock trades at a forward price-to-earnings multiple over 33. Competition in China remains difficult, and the company now battles healthcare giants Johnson & Johnson, Medtronic, and Stryker in robotic surgical systems. The expiration of Affordable Care Act subsidies and rising GLP-1 drug usage have also impacted procedure volumes. However, the company's Asian revenue still jumped 20% year-over-year in Q2, suggesting these headwinds aren't insurmountable.

Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.

Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.